(Alliance News) -Â GlaxoSmithKline PLC and Vir Biotechnology Inc on Monday said results from the phase three Comet-Ice trial were positive for its Covid-19 treatment, sotrovimab.
The trial showed that sotrovimab, an investigational SARS-CoV-2 monoclonal antibody, "significantly" reduced the risk of hospitalisation or death among high-risk adult outpatients with mild-to-moderate Covid-19.
The primary efficacy analysis of all 1,057 patients in the trial demonstrated a 79% reduction in hospitalisation for more than 24 hours or death due to any cause by day 29 compared to placebo, meeting the primary endpoint of the trial.
The firms plan to submit the results to a peer-reviewed journal for publication.
"Effective medicines to treat those who become infected with SARS-CoV-2 remain a critical part of the solution to this pandemic. We are working diligently to increase access to sotrovimab in the US and across the globe, including evaluating the potential to simplify administration with an intramuscular formulation," said Christopher Corsico, senior vice president for Development at GSK.
The firms also noted that the US National Institutes of Health has updated its Covid-19 treatment
guidelines to recommend sotrovimab for non-hospitalised patients with mild-to-moderate disease who are at high risk of clinical progression.
Shares in GSK were down 0.5% at 1,416.80 pence in London on Monday.
By Lucy Heming;Â lucyheming@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Glaxosmithkline (GSK)